By Colin Kellaher 

Pfizer Inc. on Tuesday said it expects earnings this year will top Wall Street forecasts amid surging demand for its Covid-19 vaccine.

The New York drugmaker expects adjusted full-year earnings of $3.00 to $3.10 a share, Chairman and Chief Executive Albert Bourla said at a conference.

Analysts polled by FactSet, on average, were expecting Pfizer to post an adjusted profit of $2.96 a share in 2021.

In a filing with the U.S. Securities and Exchange Commission, Pfizer noted that its forecast reflects its current expectations and assumptions regarding the impact of the Covid-19 pandemic, including its vaccine supply and contracts, which the company said remain dynamic.

BioNTech SE, Pfizer's partner on the Covid-19 vaccine, on Monday said the companies were aiming to supply up to two billion doses of the vaccine this year.

Pfizer said it will provide more detailed guidance on Feb. 2, when it reports its fourth-quarter results.

Shares of Pfizer were recently down 2.2% at $36.94.


Write to Colin Kellaher at


(END) Dow Jones Newswires

January 12, 2021 12:17 ET (17:17 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.